BUZ INVESTORS PRESS RELEASE ZDPY Eliminates Current Debt Zoned Properties, Inc. (ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties

Zoned Properties, Inc. (ZDPY) Establishes Corporate Headquarters at Medical Marijuana Business Park in Tempe

Zoned Properties’ Primary Arizona Tenant Establishes Corporate Headquarters at Medical Marijuana Business Park in Tempe

New Lease Agreement Adds Additional 2,500 square feet of Leased Space

BUZ INVESTORS PRESS RELEASE ZDPY Eliminates Current Debt Zoned Properties, Inc. <span data-recalc-dims=(ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties" width="300" height="168" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/1ZDPY.banner-1-680x380.jpg?resize=300%2C168 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/1ZDPY.banner-1-680x380.jpg?resize=680%2C380 680w" sizes="(max-width: 300px) 100vw, 300px" />

FOREX INVESTORS   PRESS RELEASE   Zoned Properties, Inc. (ZDPY), a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed medical marijuana industry, today announced it has signed a five-year commercial lease agreement with its primary tenant in Arizona, Hana Meds, to establish their Corporate Headquarters at its Medical Marijuana Business Park in Tempe, Ariz.

The renovated corporate suite includes 2,500 square feet of office and conference space, which will provide a cornerstone to base their corporate operations. Hana Meds will become the premier, anchor tenant for the property. The licensed medical marijuana tenant plans to establish a comprehensive, vertically-integrated operation at the Medical Marijuana Business Park, including all stages of medical marijuana business activities.




Zoned Properties, Inc

 

“We are pleased to further expand our relationship with Hana Meds by providing newly renovated corporate office space that is conveniently located next to their licensed medical marijuana facilities. We are inspired by our tenant’s strategic goals to capture market share by controlling their own standards of product development and distribution within every aspect of the vertically-integrated business process,” commented Bryan McLaren, Chief Executive Officer of Zoned Properties. “The time and effort our team has invested in developing this property as a state-of-the-art, sustainable facility has helped to persuade our tenant to establish its corporate headquarters at the Business Park, validating proof of concept for the property. This agreement demonstrates our mutual commitment to the City of Tempe for economic development as the licensed medical marijuana industry continues its rapid expansion.”

Under the terms of the five-year lease agreement, which commences on July 1, 2017, monthly rental payments of $1,800 per month will begin on October 1, 2017. The tenant expects to generate a significant number of new jobs as their operations continue to grow.

About Zoned Properties, Inc. (ZDPY):

Zoned Properties is a strategic real estate development firm whose primary mission is to identify, develop, and lease sophisticated, safe, and sustainable properties in emerging industries, including the licensed medical marijuana industry. The Company acquires commercial properties that face unique zoning challenges and identifies solutions that can potentially have a major impact on the cash flow and property value. Zoned Properties targets commercial properties that can be acquired and re-zoned for specific purposes. Zoned Properties does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substances Act.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




mCig Announces 5 Million Reduction in Shares Outstanding

mCig, Inc., (MCIG ) Provides Shareholder Update on Corporate Developments

|Chart | Calendar   | TRADE NOW | mCig 

MCIG Provides Shareholder Update on Corporate Developments

 

BUZ INVESTORS PRESS RELEASE Provides Shareholder Update  mCig, Inc., ( OTCQB : MCIG ), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry provides shareholders with a recap of FY2017 highlights, successes and FY2018 outlook and expansion.
Key Highlights of FY2017:

Net Sales increased to $4.5 million, a 158% increase year to year comparison, and a 1,294% increase for the 4th quarter compared to same period last fiscal year
Net income of $1.5 million compared to a $1.4 million loss from the previous year, and an increase of $2.9 million net earnings
Cash and cash equivalents of $1.6 million compared to $0.1 million from the previous year (a 1,369% increase), and a 400% increase from last quarter. mCig generated $2.1 million in cash from operating activities
mCig assets increased to $6.8 million, having 6 times more assets than it does liabilities
MCIG has established 4 targets for FY2018 in which to measure its performance. Our collective strategy aims to:



Provides Shareholder Update

Take Aggressive steps to increase revenues and profits.
Reach 1 million active combined customers across all MCIG segments.
Spin-off one subsidiary into a publicly traded company, offering a share dividend to all MCIG shareholders.
Strategically enable company to conduct business in diversified sectors, both inside and out of the cannabis industry.
GROW CONTRACTORS

Grow Contractors (GC) was MCIG’s fastest and largest growing segment in FY2017. GC generated more than $1.1 million in working capital for MCIG in FY2017.

GC has successfully completed its first two contracts, Sin City and Green Leaf Farms. GC’s talent and ability to consult and construct, has made our partners capable of meeting deadlines for “fast-track” recreational licenses. Both partners have received their official State Certificate of Occupancy to allow them to begin growing cannabis. GC continues to consult for both groups and is working on hiring and building added partnership opportunities in addition to construction. Solaris and Forest Grove projects are full steam ahead and expected to finish Phase I by September. GC also completed various smaller projects in Washington and Oregon in FY2017.

While GC has expanded operations outside of Nevada, Nevada continues to remain its focal point state, and will continue to be in FY2018. With recreational cannabis sales starting in Las Vegas on July 1, 2017, the entire market is abuzz with energy. GC has received more requests for grow consultations in the last 2 months than it has in the past two years. Projects continue to line up as demand remains increasingly strong. With 45 million tourists, higher discretionary spending, and being able to purchase cannabis with the simple requirement of being 21 years of age, Nevada is expected to top Colorado revenues and historical growth patterns. With the growth potential of the recreational cannabis market emerging in Nevada, GC is well positioned for construction and consulting services in the state of Nevada for many years to come.

MCIG will continue to update the market and shareholders of GC ‘s progress through social media (Instagram, Facebook), and our websites (growcontractors.com, mciggroup.com). We believe GC has an early adopter advantage and large growth potential in Nevada, which positions the company for facility management opportunities and owning our own profitable grow in future.

CANNABIZ SUPPLY

MCIG continues to develop and strengthen its cannabis supply venture, Cannabiz Supply. The revenue for this division (100% owned by MCIG), continues to double month over month. The business has grown in various areas — selling state mandated and custom packaging, office, dispensary supplies, and vape products. The company has gained multiple accounts with distribution to every dispensary, major grower, and production facility in the state of Nevada.

MCIG will continue to foster and grow this division, and once established and perfected in Nevada, the company plans to expand into a national cannabis supply and distribution company. “The growth of the cannabis industry is unparalleled to anything I have seen in my 45 years in business,” states Cannabis Supply, CEO, Charles Fox, “and Cannabiz Supply is poised to be a major player in the packaging and supply side every step of the way.”

GIGESOFT

In April 2017 MCIG launched 420cloud.com, a mobile application available on both Android and Apple devices. A web browsable version of 420 Cloud is planned for release in the next 3 months. During the forecasted period, new areas of the application will be released and will expand on user connectivity, user experience, premium features, microtransactions, payment wallet, advertising network, additional websites connected through the app menu and expansion to user shopping through the 420 Tienda marketplace.

MCIG considers this project to be long term and ongoing, that will produce strong intellectual property and assets, while continuing to build and enhance our cannabis job listings, weedistry 420 news, cannabis social media, and more. Owning our own tech platform opens many opportunities for future growth.

Business Description

Industry: Tobacco Products » Tobacco    NAICS: 312230    SIC: 2111
Compare: NYSE:(AOI,) OTCPK:(BXNG), OTCPK:(GLLA), OTCPK:(VPRB), OTCPK:(SRUP), OTCPK:(NHLE), OTCPK:(VAPI), OTCPK:(RCGR), NYSE:(TPB), NYSE:(UVV), NYSE:(VGR), OTCPK:(SWMAF), OTCPK:(GGNPF), OTCPK:(IMBBY), OTCPK:(JAPAF), NYSE:(RAI,) AMEX:(BTI), NYSE:(MO), NYSE:(PM) » details
Traded in other countries: M06.Germany,
Headquarter Location: USA

mCig Inc is a technology company. It is engaged in manufacturing and retailing of loose-leaf Ecig.

mCig Inc was incorporated in the State of Nevada on December 30, 2010 originally under the name Lifetech Industries, Inc. Effective August 2, 2013, the name was changed from Lifetech Industries, Inc. to mCig, Inc. The Company manufactures and retails the mCig, an affordable loose-leaf eCig. It provides a smoking experience by heating plant material, waxes, and oils delivering, in the Company’s opinion, a smoother inhalation experience. It operates in two two long-term secular trends: The decriminalization and legalization of marijuana for medicinal or recreational purposes – legalizing medicinal and recreational marijuana usage is steadily on the rise not only domestically but also internationally, The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”), as smokers move away from traditional cigarettes onto e-cigarettes. Smoking tobacco causes numerous health problems, including disease and death. It competes with other sellers of electronic cigarettes, notably Lorillard, Inc., Altria Group, Inc. and Reynolds American Inc.
Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Executive Chairman Provides a Corporate Update

Invictus MD’s Executive Chairman Provides a Corporate Update

Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

BUZ INVESTORS  Corporate Update  INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) Canada’s Cannabis Company, is pleased to provide a corporate update on the back of its recently closed bought deal financing, and reprises its vision to expand and solidify its cultivation portfolio.

“Following our successful financing with Canaccord Genuity Corp., Eventus Capital Corp., Echelon Wealth Partners Inc., GMP Securities L.P. and PI Financial Corp., including the over-allotment option, for aggregate gross proceeds of $25,008,750, Invictus MD is well capitalized and prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, we now have the largest land package in Canada for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy,” added Kriznic.

Corporate Update

“When its management team visited TSX Venture Exchange (TSXV) on May 5, 2017 and opened the trading day, we shared that celebration with all those who have contributed to our success – especially our team, the board, advisers and investors,” said Kriznic.  “From our early beginnings three years ago, we had a clear goal and the desire to do something remarkable within this budding marketplace.  We have always taken pride in knowing we’re working towards becoming a source of uncompromising quality of medical cannabis and to be ready for the future new recreational market upon legalization.”

In early May, AB Ventures Inc. (“AB Ventures”), an incorporated company formed to develop a second licensed expansion facility through its common ownership with AB Laboratories Inc. (“AB Labs”) a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) which maintains a 16,000 square foot facility located near Hamilton, Ontario, closed its 100-acre land acquisition and once licensed under the ACMPR, will be used for future cannabis cultivation.  To facilitate the construction of the initial 42,000 square foot cultivation facilities, with plans to construct additional production facilities on the new land totaling 100,000 square feet, Mr. Michael Alezane has been appointed construction manager.  Considering the magnitude of AB Ventures’ land holdings and future production facilities, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, we will have the capacity for significant growth to keep pace with the growing medical and future recreational demand.

AB Labs, which has achieved full production capacity, recently conducted its first harvest with very favorable results and will shortly apply for its pre-sales inspection.

“The Company is focused on achieving increased production profile growth in the near future.  Cultivation began earlier in the month at Acreage Pharms Ltd. (Acreage Pharms), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”),” stated Trevor Dixon, President and CEO of Invictus MD. “Planning has begun for the Phase 2 build out; Acreage Pharms has an existing 6,800 square foot production facility with an expansion plan floor plate of 27,400 square feet, that sits on 150 acres of land in West Central Alberta. To facilitate the construction of Phase 2, Mr. Harmen Bangma has been appointed construction manager.” Alberta has low cost of production as a result of low energy and water costs and provides the capability to construct facilities to meet the demand that the coming adult recreational marijuana use will create. Acreage Pharms also has plans to produce extracted or oil based products oils are rapidly gaining market share in the marijuana sector.

Invictus MD’s wholly owned venture into consumer cannabis devices; Poda Technologies Ltd. (“Poda”), is set imminently for a spin out.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp., Canada’s Cannabis Company, is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Business Description

Industry: Asset Management » Asset Management    NAICS: 523999    SIC: 7299
Compare: OTCPK:(HGBL), OTCPK:(WISH), OTCPK:(PRDGF), OTCPK:(AABVF), AMEX:(RCG), NAS:(RAND), OTCPK:(GRNBF), AMEX:(NPN), OTCPK:(LDHL), AMEX:(MIW), OTCPK:(INNO), NAS:(XRDC), NAS:(GROW), OTCPK:(HALN), AMEX:(NJV), AMEX:(MAB), OTCPK:(HGHRF), AMEX:(EMI), NYSE:(MTR), AMEX:(GRF) » details
Traded in other countries: IMH.Canada, 8IS1.Germany,
Headquarter Location: Canada

Invictus MD Strategies Corp is engaged in the investment, acquisition and development of synergistic businesses in an effort to increase and sustain growth and value.

 

 

Like up on FACEBOOK

 


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

BUZ INVESTORS PRESS RELEASE eCobalt Solutions (“eCobalt” or the “Company”) is a well-established Canadian mineral exploration and mine development company listed on the Toronto Stock Exchange under the symbol ECS,

eCobalt Provides Operations and Corporate Update

|Chart | Calendar   | TRADE NOW | eCobalt

eCobalt Provides Operations and Corporate Update

BUZ INVESTORS PRESS RELEASE Corporate Update eCobalt Solutions Inc. <span data-recalc-dims=(TSX:ECS) (the "Company" or "eCobalt") is providing its shareholders an update on its wholly owned Idaho Cobalt Project (the "ICP"), " width="300" height="173" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/05/eCobalt_Solutions_Inc_sm-1-Small.jpg?resize=300%2C173 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/05/eCobalt_Solutions_Inc_sm-1-Small.jpg?resize=768%2C444 768w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/05/eCobalt_Solutions_Inc_sm-1-Small.jpg?w=831 831w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS PRESS RELEASE  Corporate Update eCobalt Solutions Inc. (TSX:ECS) (the “Company” or “eCobalt”) is providing its shareholders an update on its wholly owned Idaho Cobalt Project (the “ICP”), the only near term, environmentally permitted, primary cobalt project located in the United States.

Over the last several months, significant progress has been made on the ICP as the Company moves closer to completing a NI 43-101 compliant Feasibility Study (the “Feasibility Study”).  The ICP is comprised of the Mine and Mill located in Salmon, Idaho and the Cobalt Production Facility (the “CPF”) located on a rail head in southern Idaho.  Based on the January 5, 2017 revised Preliminary Economic Assessment report, the CAPEX required to develop the project is US$147 million, resulting in an post-tax NPV of US$113 million (discounted at 8.5%) and a post-tax IRR of 24%, using base case price of $19.50 per pound cobalt sulfate.

Recently, the price of cobalt metal reached a six year high to over US$22.00 per pound (LME – 99.3% cobalt metal).  This signifies a strong near and long term demand for cobalt driven primarily by the lithium ion battery market.  These positive market developments are timely as the Company moves the ICP into development and production to supply cobalt sulfate to the rechargeable battery market.  Cobalt sulfate is a precursor material used in the cathode of NCA (nickel cobalt aluminum) and NMC  (nickel manganese cobalt) batteries.  These new generation lithium ion batteries are forecasted to have the highest long term growth due to their superior energy density, life cycle and safety performance.



Corporate Update

>>>TRADE NOW<<<

eCobalt reports that a number of key milestones have been achieved for the Mine and Mill, most notably:

  • Feasibility Study Timeline: June 2016, eCobalt commissioned the Feasibility Study with Micon International Limited (“Micon”) and SNC-Lavalin (“SNC”) with initial results and final report due in Q1 & Q2 2017 respectively;
  • Underground Mine Model: Wireframe model, stope outlines, and draft mine design are complete;
  • Resource Model: Resource Model and Mine Schedule are nearing completion;
  • Met Drill Program: A 2,600 foot large diameter core metallurgical drill program was successfully completed on the Ram Deposit;
  • Metallurgical: The mineralized core from the met drill program is being used in a metallurgical test program to provide additional data on concentrate recoveries, hydrometallurgical processing and cobalt sulfate crystal production. The production of these cobalt sulfate crystals will be used for additional testing and for due diligence purposes by potential offtake clients
  • Engineering: Mill and concentrator design work is 95% complete.

A number of key milestones have also been achieved for the CPF, most notably:

  • Site Location: A site in Southern Idaho for the CPF has been secured under an option agreement and site geotechnical drilling has been initiated and will be used in the final building design and costing;
  • Building and Utilities: The CPF building layout has been optimized to facilitate both material movement and functionality. Idaho Power Company will be completing a power study to identify electrical infrastructure requirements;
  • Engineering: CPF mechanical equipment lists are 80% complete, electrical single lines and electrical equipment list are 70% complete, control system/philosophy has been created, and P&IDs are 70% complete.

Feasibility Study engineers have reported that there are no further foreseeable challenges for the engineering efforts at this time.

A marketing study commissioned with CRU Group was completed to provide third party market analysis required for the Feasibility Study and to support project financing decisions.  An important mandate for this study was to determine how the ICP’s cobalt sulfate grade compares with other global producers. Cobalt sulfate used as battery grade materials are required to be high purity with the lowest levels of a wide range of elements including alkali metals, heavy metals, and elements that form acids such as sulfur, chlorine and phosphorus.  It was determined that specifications of the cobalt sulfate produced from ICP ore qualify for the latest generation of NMC and NCA batteries.  These specifications were produced from the metallurgical test program that was completed by the Company in March 2016 (March 3, 2016 news release).  These results validate the Company’s progress to date and further facilitate potential offtake partnerships.  The results of the full marketing study will be included in the final Feasibility Study.

The Company recently closed a C$17.25 million bought deal led by Canaccord Genuity Corp.  The proceeds from the financing will be used to advance the ICP.  In the near term, the Company will be expanding its technical team, aggressively pursuing project financing options, beginning groundwork on the CPF site and undertake other opportunities to increase value for our shareholders.

“Additional interest in the project from potential offtake clients and senior debt lenders have been increasing as the Feasibility Study progresses towards completion,” commented Paul Farquharson, President & CEO of eCobalt.  He continued, “The strong forecasted near and long term demand for cobalt is driven primarily by the rechargeable battery and EV markets – this demand was not there in the past.  In addition, the majority of cobalt is being mined in the Democratic Republic of Congo as a by-product of copper mining operations, and from nickel mining operations elsewhere.  The ICP a very unique project for manufacturers who are seeking a fully integrated cobalt sulfate product produced safely and responsibly in an environmentally conscious manner in the United States.”

E.R. (Rick) Honsinger, P.Geo., Senior Vice President of the Company, is the Qualified Person as defined by National Instrument 43-101 who has supervised the preparation of this news release and has approved its contents.

About eCobalt Solutions Inc.

eCobalt Solutions is a well-established Toronto Stock Exchange listed company committed to providing ethically produced and environmentally sound battery grade cobalt salts, essential for the rapidly growing rechargeable battery and renewable energy sectors, made safely, responsibly and transparently in the United States.

eCobalt Solutions Inc.

“J. Paul Farquharson”

J. Paul Farquharson
President & CEO

Like up on FACEBOOK
Market quotes are powered by
TradingView.com


Commodities ( Gold ) ( Silver ) ( Lithium )




VPR Brands, LP will be participating at TPE Tobacco Plus Expo in Las Vegas showcasing their newest products for 2017

$VPRB Announces the Grand Opening of Its Corporate Vape And Smoke Store

VPR Brands announces the grand opening of its corporate Vape and Smoke store

BUZ INVESTORS Vape And Smoke Store - VPR Brands, LP (OTC PINK: VPRB) announces the grand opening of its corporate wholesale and retail showroom

BUZ INVESTORS Vape And Smoke Store– VPR Brands, LP (OTC PINK: VPRB) announces the grand opening of its corporate wholesale and retail showroom and store at its headquarters in Fort Lauderdale, Florida. The newly updated storefront showcases all of our flagship brands and also carries popular competing brands within the vaping segment. In addition to Vapor products and vast assortment of e liquids, the store also has a top of the line selection of Glass as well as smoking accessories on display and available for sale ranging from affordable to handmade one off high end pieces.

“We are capitalizing on our premier location and our existing corner street front space within our building, which also contains our administrative offices and warehouse. We have been partially open since January while filling and remodeling the store. Within that time frame, we already expanded the footprint once to increase our product offering and have more room to expand the store as sales grow,” said Kevin Frija, CEO of VPR Brands LP. “Taking advantage of our location and space is an untapped revenue source, which was a no brainer and will help us generate income and ROI immediately with minimal investment. Additionally, it gives us an updated wholesale showroom to use for our wholesale accounts who come visit us.”





 

OTHER STORIES BUZ TRADERS FOLLOW

Vape And Smoke Store

“By having the store as a portion of our building, it not only helps us monetize our great location, but also gives us direct access to real time customer opinions. It is great to have a real store format where our team can conduct mini focus groups completely impromptu and get real feedback on new products in the pre-launch phase. The store does an amazing job showcasing our diverse range of product; I am very happy with the way it turned out,” says Dan Hoff, COO of VPR Brands LP

Our official grand opening party for The Vape and Smoke Store is planned for 4/20/2017, come join us for 4-20% off discounts all day long!

About VPR Brands LP:
VPR Brands is a technology company, whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the company on the web at www.vprbrands.com.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016 FINANCIAL RESULTS AND CORPORATE UPDATE

Download PDF

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 23, 2017 AT 10:00 AM EDT

Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016

Buz Investors PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016   — Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported financial results for the fourth quarter and fiscal year of 2016 and provided an update on the Company’s recent developments.




OTHER STORIES BUZ TRADERS FOLLOW

PIERIS PHARMACEUTICALS REPORTS FULL-YEAR 2016  

“2016 was a highly productive year for Pieris marked by: i) broad advancement of our proprietary clinical and preclinical programs, ii) completion of a $16.5 million private placement financing that strengthened our shareholder base, iii) achievement of several milestones in our collaborative programs, and iv) expansion of our Board of Directors and the appointment of a Chief Business Officer. At several R&D conferences throughout the year, including in the fourth quarter at the annual meeting of the Society of Immunotherapy of Cancer (SITC), we presented preclinical data demonstrating a differentiated mode of action for PRS-343, our lead 4-1BB (CD137)-based HER-2 bispecific immuno-oncology program, which remains on track for Phase I initiation in the first half of this year,” said Stephen Yoder, President and CEO. “Our targeted, inhaled asthma program, PRS-060, which engages the IL4a receptor, is differentiated from systemically administered therapies, and is on track to enter a Phase I study in mid-2017. Pieris has also completed dosing of all patients in a Phase Ib single ascending dose study of our most advanced program, PRS-080, in dialysis-dependent chronic kidney disease patients and expects to present this data in the first half of this year.”

“With these accomplishments behind us, we started 2017 on a very strong note, as we have already consummated a multi-target, multi-year, transformative partnership in the immuno-oncology space with Servier, the second largest pharmaceutical company in France. This alliance includes our dual checkpoint inhibitor, PRS-332, as well as four additional bispecific programs and may be expanded to eight total programs. Notably, Pieris has the option to co-develop and retain full US rights for four of these programs, including PRS-332, and is eligible to receive up to approximately $1.8 billion in total potential milestones, and up to low double-digit royalties on potential future product sales, in addition to having received an upfront payment of approximately $31.0 million. We also recently announced a regional partnership in Japan with Aska Pharmaceutical Co., Ltd. for PRS-080, which will allow us to invest in manufacturing efficiencies and drug supply for additional clinical studies beyond our planned Phase IIa study, which we believe could help set the stage for additional potential partnerships outside of Japan, following the completion of that study. Finally, we continue to advance our preclinical portfolio of novel multispecific therapeutic proteins, as well as our existing partnerships, while continuing to explore additional collaborations. We ended the fourth quarter in a solid financial position and, considering the upfront payments we have received in the first quarter of 2017, we believe we can manage our financial runway into 2019, enabling us to reach several key value inflection points along the way.”

Fourth Quarter and 2016 Highlights:

  • Advanced PRS-080 through an ongoing Phase Ib single ascending dose study in anemia of chronic disease, having completed patient dosing in early 2017, which will assess the effect of PRS-080 on iron mobilization and transferring saturation in dialysis-dependent anemia patients.
  • Advanced PRS-343 through IND-enabling studies and towards a first-in-patient study for HER-2 positive cancers.
  • Advanced PRS-060, a novel inhaled therapeutic for moderate to severe asthma, through IND-enabling studies.
  • Advanced our novel multi-checkpoint blockade bispecific, PRS-332, comprised of an anti-PD-1 antibody genetically linked to an existing Anticalin against an undisclosed checkpoint, through preclinical studies.
  • Strengthened our Board of Directors with the addition of Julian Adams, Ph.D. and Christopher Kiritsy.
    • Dr. Adams is the former President of Research & Development at Infinity Pharmaceuticals. During his career, Dr. Adams has had global responsibility for multiple drug discovery programs, including the discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy, and Viramune® (nevirapine) for HIV. Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation.
    • Mr. Kiritsy is the Chief Executive Officer and co-founder of Arisaph Pharmaceuticals. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from start-up to a highly profitable, publicly traded, commercial company.
  • Appointed Claude Knopf as Senior Vice President and Chief Business Officer. Prior to joining Pieris, Mr. Knopf served as Global Head Business Development & Licensing/Mergers and Acquisitions at Baxalta. Prior to joining Baxalta, a spin-off of Baxter where he held a similar position for the Baxter Bioscience Division up to the creation of Baxalta. Prior to joining Baxter, Mr. Knopf held several business development, alliance management, and licensing and marketing roles at Novartis, most recently as the Head of Business Development and Licensing, Strategic Planning, Vaccines European Region.

Fiscal Year Financial Update:

Cash Position – Cash and cash equivalents totalled $29.4 million as of December 31, 2016, compared to $29.3 million as of December 31, 2015. The increase in cash was driven primarily by the $16.5 million gross private placement financing completed in June 2016 offset by cash used in our operating activities.

R&D Expense ­ – Research and development expenses were $19.7 million for the year ended December 31, 2016, compared to $8.2 million for the year ended December 31, 2015. The $11.5 million increase was primarily due to a $5.6 million increase in pre-clinical development and CMC costs for PRS-343 as we carry out IND enabling studies and increased development costs for our other PRS-300 series programs, and a $1.2 million increase in CMC costs associated with PRS-060 as we carry out IND enabling studies, offset by a $0.2 million decrease for our PRS-080 program due to the completion of our Phase Ia clinical trial in 2015. Other R&D expenses also increased by $4.9 million primarily due to higher personnel-related expenses including stock-based compensation expense and increased costs for license fees, as well as higher legal and consulting costs. Additionally, costs for general lab supplies increased due to an upturn in program activities.

G&A Expense – General and administrative expenses for the year ended December 31, 2016 were $8.9 million, compared to $8.4 million for the year ended December 31, 2015. The $0.5 million increase in G&A expenses is primarily due to an increase in personnel-related costs, including stock-based compensation expense, higher legal and recruiting costs, and costs associated with being a public company such as financial printing costs and transaction fees.

Net Loss – Net loss was $22.8 million or ($0.55) per share for the year ended December 31, 2016, compared to a net loss $14.1 million or ($0.41) per share for the year ended December 31, 2015.

Upcoming Milestones:

The Company expects to reach the following milestones during 2017:

  • PRS-080: Present Phase Ib data and initiate a multi-dose, Phase IIa study in dialysis-dependent anemia patients during the second quarter, which we estimate will be completed by the end of 2017.
  • PRS-343: Initiate a Phase I multi-ascending dose study involving a range of HER2-positive solid cancers representing unmet medical needs (such as breast, gastrointestinal and bladder cancers) in the first half of 2017.
  • PRS-332: Progress preclinical evaluation in collaboration with Servier, with IND-enabling activities planned for later in 2017.
  • PRS-060: Initiate a Phase I study in mid-2017.

Upcoming Scientific Presentations:

  • PRS-343: IND-enabling data informing the design of a first-in-patient clinical trial for PRS-343 will be presented in a poster session at next month’s Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C. The poster will be presented on Tuesday, April 4, 2017 in a session from 8am to 12pm EDT.

Conference Call:

Pieris management will host a conference call beginning at 10:00 AM Eastern Daylight Time on Thursday, March 23, 2017, to discuss the full year financial results and provide a corporate update. You can join the call by dialing +1-877-407-8920 (US & Canada) or +1-412-902-1010 (International). An archived replay of the call will be available by dialling +1-877-660-6853 (US & Canada) or +1-201-612-7415 (International) and providing the Conference ID #: 13657695.

About Pieris Pharmaceuticals :

Pieris is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. Pieris has partnerships with Servier, ASKA, Roche, Sanofi, Daiichi Sankyo and Zydus. For more information visit www.pieris.com.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Japan Domestic Corporate Goods Price Index | 1960-2017 | Data | Chart

Buz Investors Japan Domestic Corporate Goods Price Index

Buz Investors  Japan Domestic Corporate Goods Price Index Producer Prices in Japan increased to 97.70 Index Points in January from 97.10 Index Points in December of 2016. Producer Prices in Japan averaged 90.15 Index Points from 1960 until 2017,




OTHER STORIES BUZ TRADERS FOLLOW

 Japan Domestic Corporate Goods Price Index

reaching an all time high of 115.50 Index Points in September of 1980 and a record low of 48.70 Index Points in June of 1962. In Japan, the Producer Price Index measures the average change in price of goods and services sold by manufacturers and producers in the wholesale market during a given period. This page provides – Japan Producer Prices – actual values, historical data, forecast, chart, statistics, economic calendar and news.

 




The distributed ledger division at Finlync has implemented the world’s first agnostic blockchain integrator for ERP systems. Their latest integrator allows seamless plug-and-play integration to SAP, for Ethereum and Hyperledger; with more platforms following suit. ERPs, like SAP, are the central backbone for most large corporates, processing data such as purchase orders, deliveries, invoices and payment instructions. Integration therefore allows for true data interoperability for such corporate banking services like Trade Financing, Payments and Contract Management. APAC Technology Director, Peter Klein, said that the “Finlync SAP-DL Integrator gives effortless process integration with trusted communication to Bank’s Distributed Ledger platforms. This allows corporates to experience secure access and centralised control – all within their already existing ERP”. Banks and financial institutions can benefit from a risk-adverse solution to onboard their corporate clients quickly and efficiently to their BlockChain offerings. Peter says “Banks are working with us to secure their existing client relationships, whilst opening new revenue channels, by bringing ERP corporates to the multi-party value chain.” Finlync have an extensive history of implementing ISO20022 messaging standards for ERP to Bank Communication. Whilst leveraging on this experience, they are now evaluating for new and effective messaging integration in the distributed ledger. The SAP-DL Integrator has a light footprint which can integrate even with older versions of SAP, but leverages innovative, user friendly and attractive HTML5 type user interfaces. The technology utilizes API calls for real-time integration of ERP data to blockchains. Finlync are running demos of the latest solution and pursuing for continual collaboration.

Corporate ERP Integration to Distributed Ledger Technology

Corporate ERP Integration to Distributed Ledger Technology

The distributed ledger division at Finlync has implemented the world’s first agnostic blockchain integrator for ERP systems.  Their latest integrator allows seamless plug-and-play integration to SAP, for Ethereum and Hyperledger; with more platforms following suit.    ERPs, like SAP, are the central backbone for most large corporates, processing data such as purchase orders, deliveries, invoices and payment instructions.  Integration therefore allows for true data interoperability for such corporate banking services like Trade Financing, Payments and Contract Management.    APAC Technology Director, Peter Klein, said that the “Finlync SAP-DL Integrator gives effortless process integration with trusted communication to Bank’s Distributed Ledger platforms.  This allows corporates to experience secure access and centralised control – all within their already existing ERP”.  Banks and financial institutions can benefit from a risk-adverse solution to onboard their corporate clients quickly and efficiently to their BlockChain offerings.  Peter says “Banks are working with us to secure their existing client relationships, whilst opening new revenue channels, by bringing ERP corporates to the multi-party value chain.”   Finlync have an extensive history of implementing ISO20022 messaging standards for ERP to Bank Communication. Whilst leveraging on this experience, they are now evaluating for new and effective messaging integration in the distributed ledger.    The SAP-DL Integrator has a light footprint which can integrate even with older versions of SAP, but leverages innovative, user friendly and attractive HTML5 type user interfaces.  The technology utilizes API calls for real-time integration of ERP data to blockchains.    Finlync are running demos of the latest solution and pursuing for continual collaboration.

The distributed ledger division at Finlync has implemented the world’s first agnostic blockchain integrator for ERP systems.  Their latest integrator allows seamless plug-and-play integration to SAP, for Ethereum and Hyperledger; with more platforms following suit.

ERPs, like SAP, are the central backbone for most large corporates, processing data such as purchase orders, deliveries, invoices and payment instructions.  Integration therefore allows for true data interoperability for such corporate banking services like Trade Financing, Payments and Contract Management.

APAC Technology Director, Peter Klein, said that the “Finlync SAP-DL Integrator gives effortless process integration with trusted communication to Bank’s Distributed Ledger platforms.  This allows corporates to experience secure access and centralised control – all within their already existing ERP”.

Banks and financial institutions can benefit from a risk-adverse solution to onboard their corporate clients quickly and efficiently to their BlockChain offerings.  Peter says “Banks are working with us to secure their existing client relationships, whilst opening new revenue channels, by bringing ERP corporates to the multi-party value chain.”

Finlync have an extensive history of implementing ISO20022 messaging standards for ERP to Bank Communication. Whilst leveraging on this experience, they are now evaluating for new and effective messaging integration in the distributed ledger.

The SAP-DL Integrator has a light footprint which can integrate even with older versions of SAP, but leverages innovative, user friendly and attractive HTML5 type user interfaces.  The technology utilizes API calls for real-time integration of ERP data to blockchains.

Finlync are running demos of the latest solution and pursuing for continual collaboration.

BlueOcean NutraSciences Inc. Provides a Corporate Update Post Financing Close

BlueOcean NutraSciences Inc. Provides a Corporate Update Post Financing Close

BlueOcean NutraSciences Inc. Provides a Corporate Update Post Financing Close

BlueOcean NutraSciences Inc. Provides a Corporate Update Post Financing Close

BlueOcean NutraSciences Inc. (“BlueOcean” or the “Company“) (TSX-V: BOC) is pleased to provide a corporate update, post the closure of its $2.5M Private Placement in December 2016.

Corporate Strategy
 
Funding is now in place for both manufacturing and effectively marketing BlueOcean’s broadening suite of shrimp oil based supplements in 2017. Actions taken to date in 2017 include:

  1. New inventory of an upgraded Pure Polar® product line with improved formulas and packaging of all three SKU’s (Regular Strength, Double Strength and Extended Release) are being manufactured in Canada for delivery during the first quarter of 2017.
  2. Two additional brands, SportAXTM and JointAXTM are also being manufactured in Canada with brand specific formulas and packaging targeted at the large sports & fitness and joint supplement markets. SportAXTM and JointAXTM will both be launched in March, 2017.
  3. As previously reported in its news release dated December 20, 2016, BlueOcean has acquired 100% of the issued and outstanding shares of Pure Polar Labs Inc. (“Pure Polar”) from CMAX Technologies Inc. (“CMAX”) and Heuer M.D. Research Inc. (“Heuer”), thereby taking control of its retail fulfillment subsidiary to drive maximum value for BlueOcean shareholders.
  4. CMAX’s CEO Jeff Renwick and Dr. Marvin Heuer, CEO of Heuer have agreed to join BOC’s Advisory Board as experts in drug and supplement product formulation.

Marketing Development

As previously reported in its news release dated January 12, 2017, BlueOcean has retained the Marketing services of Jurgen Pauquet on an interim basis to guide BOC’s E-Commerce, DRTV and other media marketing strategies. Jurgen was previously the SVP of Digital Marketing & E-Commerce International at Guthy Renker. Jurgen brings decades of successful E-Commerce experience to BOC’s core E-Commerce strategy, as well as DRTV, endorsements and other marketing initiatives that the Company plans to undertake in 2017.

Corporate Reorganization

BlueOcean has now successfully implemented its complete production value chain including third-party shrimp shell feedstock relations and patented shrimp oil processing, consumer brands product encapsulation and packaging, and sales fulfillment, all supported by its marketing strategy to drive sales of its various consumer shrimp oil brands. This has led to the following management reorganization:

  1. Sam Kanes, founding Director of BlueOcean, takes on the role of VP, Strategy and IR; and
  2. Dil Vashi has been promoted to VP Business Operations.

2017 Sales Outlook

The global market for bulk ($150M 2016 est.) and retail ($1B 2016 est.) krill oil supplements has stabilized and is now growing at an estimated 13% compound average growth rate (“CAGR”) (Persistence Market Research). The global retail market for natural astaxanthin (“AX”) supplements (primarily derived from microalgae) is estimated to be worth $100M (2016 est.) and continues to rise sharply with forecasts of up to 15% CAGR through 2023 (Global Market Insights). While the supply of natural astaxanthin continues to increase, the demand for the product is also increasing in sync, thereby maintaining the high value of the product.

All BlueOcean product SKUs contain shrimp oil, which has a natural combination of both phospholipid omega-3s as in krill, and high levels of natural astaxanthin. SportAXTM and JointAXTM SKU’s will compete directly against algae based AX in the sports/fitness and glucosamine-dominated joint supplements markets, broadening BOC’s product lines and target markets beyond the heart health market that krill only focuses on.

Pure Polar® and new SKU orders from larger Canadian and US retail chains are targeted to close by June 30, 2017 with September/October 2017 delivery dates. BlueOcean will use its current limited shrimp oil inventory made from the 2016 season, to fulfill its growing E-Commerce business.

About BlueOcean

BlueOcean NutraSciences Inc. is a Canadian listed public Company that is focused on developing sustainable, specialty nutraceutical products targeted at the rapidly growing natural health products markets, with a current focus on the $4B omega-3 heart health supplement market, the $9Bn joint health market, and the $10B sports supplement market. BlueOcean’s proprietary shrimp oil ingredient contains high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA, enabling the product to be targeted across all three markets described above.